Can the reprogrammed cancer cells serve as an alternative source of (induced) cancer stem cells?
Abstract
Background: Cancer stem cells (CSCs) constitute a small and elusive subpopulation of cancer cells within a tumor mass and are characterized by stem cell properties. Reprogrammed CSCs exhibit similar capability to initiate tumor growth, metastasis, and chemo- and radio-resistance and have similar gene profiles to primary CSCs. However, the efficiency of cancer cell reprogramming remained relatively low. There is limited literature available on the reprogramming of lung cancer cells. Hence, in this study we have conducted reprogramming of human lung cancer cells towards more benign type of cells.
Materials and methods: The reprogramming process was carried out with the use of STEMCCA vector. We have investigated the gene expression profile of induced CSCs (iCSCs) using the microarray technique.
Results: The lung iCSCs demonstrate morphology characteristics of induced pluripotent stem cells (iPSCs) and gene expression profile that significantly differ from cells before reprogramming. We have also presented the elevated level of expression of genes associated with the cancer stemness and thus revealed new interesting CSC-like molecular markers.
Conclusions: These preliminary results demonstrated that the reprogramming process in vitro leads to the remarkable changes in cells at the gene level and has potential to be an alternative method of generating CSC-like cells.
Keywords: cancer stem cellsnon-small cell lung cancerreprogramminggene expression profile
References
- Alaswad M. Locally advanced non-small cell lung cancer: current issues and recent trends. Rep Pract Oncol Radiother. 2023; 28(2): 286–303.
- Sato D, Sasaki M, Nakaguchi Y, et al. Differences between professionals in treatment planning for patients with stage III lung cancer using treatment-planning QA software. Rep Pract Oncol Radiother. 2023; 28(5): 671–680.
- Vojtíšek R. What is the current role of prophylactic cranial irradiation in the treatment algorithm for small cell lung cancer? Rep Pract Oncol Radiother. 2023; 28(5): 698–706.
- Niemira M, Collin F, Szalkowska A, et al. Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). Cancers (Basel). 2019; 12(1).
- Romeo HE, Barreiro Arcos ML. Clinical relevance of stem cells in lung cancer. World J Stem Cells. 2023; 15(6): 576–588.
- Gong L, Yan Q, Zhang Yu, et al. Cancer cell reprogramming: a promising therapy converting malignancy to benignity. Cancer Commun (Lond). 2019; 39(1): 48.
- Kim J, Zaret KS. Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO J. 2015; 34(6): 739–747.
- Zimmermannova O, Ferreira AG, Pereira CF, et al. Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Front Immunol. 2021; 12(69): 714822–97.
- Fujino S, Miyoshi N, Kitakaze M, et al. Clinical Study Group of Osaka University, Colorectal Cancer Treatment Group (CSGOCG). Adenylosuccinate lyase enhances aggressiveness of endometrial cancer by increasing killer cell lectin-like receptor C3 expression by fumarate. Lab Invest. 2018; 98(4): 449–461.
- Stelcer E, Komarowska H, Jopek K, et al. Biological response of adrenal carcinoma and melanoma cells to mitotane treatment. Oncol Lett. 2022; 23(4): 120.
- Stelcer E, Milecka P, Komarowska H, et al. Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line. Front Endocrinol (Lausanne). 2020; 11: 561370.
- Stelcer E, Jopek K, Blatkiewicz M, et al. Gene expression profile of hiPSC-derived cells differentiated with growth factors, forskolin and conditioned medium from human adrenocortical cell line. Adv Clin Exp Med. 2024; 33(4): 397–407.
- Méry B, Guy JB, Espenel S, et al. Targeting head and neck tumoral stem cells: From biological aspects to therapeutic perspectives. World J Stem Cells. 2016; 8(1): 13–21.
- Prabavathy D, Swarnalatha Y, Ramadoss N. Lung cancer stem cells-origin, characteristics and therapy. Stem Cell Investig. 2018; 5: 6.
- Otte J, Dizdar L, Behrens B, et al. FGF Signalling in the Self-Renewal of Colon Cancer Organoids. Sci Rep. 2019; 9(1): 17365.
- Gilazieva Z, Ponomarev A, Rutland C, et al. Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine. Cancers (Basel). 2020; 12(10).
- Liu M, Tu J, Gingold JA, et al. Cancer in a dish: progress using stem cells as a platform for cancer research. Am J Cancer Res. 2018; 8(6): 944–954.
- Pan XY, Tsai MH, Wuputra K, et al. Application of Cancer Cell Reprogramming Technology to Human Cancer Research. Anticancer Res. 2017; 37(7): 3367–3377.
- Saito S, Lin YC, Nakamura Y, et al. Potential application of cell reprogramming techniques for cancer research. Cell Mol Life Sci. 2019; 76(1): 45–65.
- Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011; 71(13): 4640–4652.
- Bang JS, Choi NaY, Lee M, et al. Reprogramming of Cancer Cells into Induced Pluripotent Stem Cells Questioned. Int J Stem Cells. 2019; 12(3): 430–439.
- Chao MP, Gentles AJ, Chatterjee S, et al. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell. 2017; 20(3): 329–344.e7.
- Ting KKY, Ting KKY, Ting KKY, et al. Oxidized Low-Density Lipoprotein Accumulation Suppresses Glycolysis and Attenuates the Macrophage Inflammatory Response by Diverting Transcription from the HIF-1α to the Nrf2 Pathway. J Immunol. 2023; 211(10): 1561–1577.
- Tafani M, Perrone GA, Pucci B, et al. Reprogramming cancer cells in endocrine-related tumors: open issues. Curr Med Chem. 2014; 21(9): 1146–1151.